Study Summary
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Want to learn more about this trial?
Request More InfoInterventions
huCART19-IL18BIOLOGICAL
autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Pennsylvania | Philadelphia | Pennsylvania | United States |